Abstract
Sleep disorders and pain are symptoms that have been increasingly recognized as non-motor symptoms in Parkinson's disease, these no motor symptoms can be some of the most disabling and significantly impact the quality of life of patients that suffer it. This article discusses the importance of the recognition, approach and treatment of the most frequent sleep disorders in patients with Parkinson's disease, such as MOR sleep behavior disorder, insomnia and fragmented sleep, daytime sleepiness and restless legs syndrome, as well as the general approach to pain in patients with this disease.
References
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The Priamo study : A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. 2009; 24(11):1641-9.
Pandey S, Bajaj BK, Wadhwa A, Anand KS. Impact of sleep quality on the quality of life of patients with Parkinson's disease: A questionnaire based study. Clin Neurol Neurosurg. 2016;148:29-34.
Suzuki K, Okuma Y, Hattori N, Kamei S, Yoshii F, Utsumi H, Iwasaki Y, Iijima M, Miyamoto T, Miyamoto M, Hirata K. Characteristics of sleep disturbances in Japanese patients with Parkinson's disease. A Study using Parkinson's disease sleep scale. Mov Disord. 2007;22(9):1245-51.
Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord. 1998;13(6):895-9.
Comella CL. Sleep disorders in Parkinson's disease: An overview. Mov Disord. 2007. Supl. 17:S367-73.
Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, MacPhee G, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using non-motor symptoms questionnaire in 545 patients. Mov Disord. 2007;22(11):1623-9.
Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson's disease : dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464-74.
Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5(3):235-45.
Peeraully T, Yong M, Chokroverty S. Sleep and Parkinson's disease : A review of case-control polysomnography studies. Mov Disord. 2012;27(14):1729-37.
Peeraully T, Yong MH, Chokroverty S, Tan EK. Sleep and Parkinson's disease : A review of case-control polysomnography studies. Mov Disord. 2012;27(14):1729-37.
Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, et al. Scales to assess sleep impairment in Parkinson's disease : critique and recommendations. Mov Disord. 2010;25(16):2704-16.
Martinez-Martin P, Visser M, Rodriguez-Blazquez C, Marinus J, Chaudhuri KR, Hilten JJ Van. SCOPA-Sleep and PDSS : two scales for assessment of sleep Disorder in Parkinson's disease. Mov Disord. 2008;23(12):1681-8.
Marti P, Salvador C, Gonza S. Parkinson's disease sleep scale: validation study of a Spanish version. Mov Disord. 2004;19(10):1226-32.
Metta V, Sixel-do F, Martinez-Martin P, Chaudhuri KR. Parkinson's disease sleep scale - validation of the revised version PDSS-2. Mov Disord. 2011;26(4):644-52.
Escobar-Córdoba F, Eslava-Schmalbach JH. Validación colombiana del índice de calidad de sueño de Pittsburgh. Rev Neurología. 2005;40:150-5.
Iranzo A, Silber MH. Stop, look, and listen: sleep in movement disorders. Mov Disord. 2017;32(5):633-5.
Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146(5):1387-94.
Arnulf I. Review MOR sleep behavior disorder: motor manifestations and pathophysiology semiology of TC-MOR in PD (behavior and clinical aspects). Mov Disord. 2012;27(6):677-89.
Postuma RB, Gagnon J, Vendette M, Montplaisir JY Idiopathic MOR sleep behavior disorder in the transition to degenerative disease. Mov Disord. 2009;24(15):2225-32.
Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic MOR sleep behavior disorder. Neurology. 2009;72(15):1296-300.
Berg D, Postuma RB, Adler CH, Bloem BR. CME MDS research criteria for prodromal Parkinson's disease key definition features of prodromal PD. Mov Disord. 2015;30(12):1600-9.
Pilotto A, Heinzel S, Suenkel U, Lerche S, Brockmann K, Roeben B, et al. Application of the movement disorder society prodromal Parkinson' s disease research criteria in 2 independent prospective cohorts. Mov Disord. 2017;32(7):1025-34.
Louis EKS. Review MOR sleep behavior disorder in Parkinson's disease and other synucleinopathies. Mov Disord. 2017;32(5):17-23.
Gallea C, Ewenczyk C, Degos B, Welter M. Pedunculopontine network dysfunction in Parkinson's disease with postural control and sleep disorders. Mov Disord. 2017;32(5):693-704.
Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: A prospective cohort comparison with other phenotypes. JAMA Neurol. 2015;72(8):863-73.
Amara AW, Chahine LM, Videnovic A. Treatment of sleep dysfunction in Parkinson's disease dopaminergic medications. Curr Treat Options Neurol. 2017;19(7):26. doi: 10.1007/s11940-017-0461-6.
Mcgrane IR, Leung JG, St EK, Boeve BF. Melatonin therapy for MOR sleep behavior disorder : a critical review of evidence. Sleep Med. 2015;16(1):19-26.
Li SX, Lam SP, Zhang J, Yu MW, Chan JW, Liu Y, et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med. 2016;21:114-20.
Menza M, Dobkin RD, Marin H, Gara M, Bienfait K, Dicke A, Comella CL, Cantor C, Hyer L. Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo. Mov Disord. 2010;25(11):1708-14.
Fifel K. Alterations of the circadian system in Parkinson's disease patients. The circadian system : general concepts circadian abnormalities in pd patients. Mov Disord. 2017;32(5):682-92.
Videnovic A. Management of sleep disorders in Parkinson's disease and multiple system atrophy. Mov Disord. 2017;32(5):659-68.
Reynolds GO, Otto MW, Ellis TD, Cronin-Golomb A. The therapeutic potential of exercise to improve mood, cognition, and sleep in Parkinson's disease potential of exercise interventions for mood treatment of mood symptoms in PD. Mov Disord. 2016;31(1):23-38.
Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, Postuma RB. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson. Parkinsonism Relat Disord. 2013;19(7):670-5.
Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease : a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513-20.
Trenkwalder C1, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, t al. Rotigotine Effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90-9.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson's disease - An evidence-based medicine review. Mov Disord. 2019;34(2):180-98.
Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, Magalhães MC, de Lourdes Seabra M, de Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. J Neurol. 2007;254(4):459-64.
Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: A controlled study. Mov Disord. 2003;18(6):668-72.
Go JC, Zarranz JJ, Lezcano E. Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease. Mov Disord. 2006;21(7):983-8.
Stefani A. Restless legs syndrome and periodic leg movements in patients "with movement disorders: specific considerations issues in the diagnosis of RLS. Mov Disord. 2017;32(5):669-81.
Broen MPG, Braaksma MM, Patijn J, Weber WEJ. Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS Tool. Mov Disord. 2012;27(4):480-4.
Ford B. Pain in Parkinson's disease. Mov Disord. 2010;25(Supl. 1):S98-103.
Antonini A, Tinazzi M, Abbruzzese G, Berardelli A, Chaudhuri KR, Defazio G, Ferreira J, Martinez-Martin P, Trenkwalder C, Rascol O. Pain in Parkinson's disease : facts and uncertainties. Eur J Neurol. 2018;25(7):917-e69.
Parkinson D. Complejo sintomático no motor de la enfermedad de Parkinson. Rev Neurol Neurocir Psiquiat. 2017;45(2):51-60.
Wasner G, Deuschl G. Pains in Parkinson disease - many syndromes. Nat Rev Neurol. 2012;8(5):284-94.
Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S. King's Parkinson's disease pain scale, the first scale for pain in PD: an international validation. Mov Disord. 2015;30(12):1623-31.
Rodríguez-Violante M, Alvarado-Bolaños A, Cervantes-Arriaga A, Martínez-Martin P, Rizos A, Chaudhuri KR. Clinical determinants of Parkinson's disease-associated pain using the King's Parkinson's disease pain scale. Mov Disord Clin Pract. 2017;4(4):545-51.
Kassubek J, Chaudhuri KR, Zesiewicz T, Surmann E, Boroojerdi B, Moran K, Ghys L, Trenkwalder C. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease : a post hoc analysis of the RECOVER study. BMC Neurol. 2014;14(1):1-8.
Cattaneo C, Barone P, Bonizzoni E, Sardina M. Effects of safinamide on pain in fluctuating Parkinson's disease patients: A post-hoc analysis. J Parkinsons Dis. 2017;7(1):95-101.
Cury RG, Galhardoni R, Fonoff ET, Dos Santos Ghilardi MG, Fonoff F, Arnaut D, et al. Effects of deep brain stimulation on pain and other nonmotor symptoms in Parkinson disease. Neurology. 2014;83(16):1403-9.
Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Valis M, et al. Prolonged-release oxycodone - naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015;14(12):1161-70.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.